NCT03522935View on ClinicalTrials.gov

Subcutaneous Elafin in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

March 18, 2019

Primary Completion Date

October 25, 2019

Study Completion Date

November 18, 2020

Conditions
Pulmonary Arterial Hypertension
Interventions
DRUG

Elafin

Elafin subcutaneous.

DRUG

Placebo

Placebo subcutaneous.

Trial Locations (1)

27710

Duke Early Phase Research Unit (DEPRU), Durham

Sponsors
All Listed Sponsors
collaborator

Duke University

OTHER

collaborator

SRI International

INDUSTRY

collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

Roham T. Zamanian

OTHER